Entrectinib is an orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B, and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1, and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1, and ALK are overexpressed in a variety of cancer cell types.
Entrectinib is an oral selective inhibitor of the neurotrophic T receptor kinase (NTRK) and ROS1 that is used to treat solid tumors with NTRK gene fusion and non-small cell lung cancer with ROS1 mutations. Serum aminotransferase elevations are common during therapy but the clinically apparent liver injury is rare, although it has been reported.
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors. Entrectinib’s approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefits over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.[rx] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors.[rx] Entrectinib’s approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefits over similar ALK inhibitors such as alectinib, ceritinib, and lorlatinib due to a wider range of targets.[rx]
Mechanism of Action
Entrectinib is a tyrosine kinase inhibitor that acts on several receptors. It functions as an ATP competitor to inhibit tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC, as well as proto-oncogene tyrosine-protein kinase ROS1 and anaplastic lymphoma kinase (ALK). TRK receptors produce cell proliferation via downstream signaling through the mitogen-activated protein kinase, phosphoinositide 3-kinase, and phospholipase C-γ. ALK produces similar signaling with the addition of downstream JAK/STAT activation. Inhibition of these pathways suppresses cancer cell proliferation and shifts the balance in favor of apoptosis resulting in the shrinking of tumor volume.
Indications
- Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment of NTRK gene fusion-positive solid tumors which have metastasized or for which surgical resection is likely to result in severe morbidity and for which has progressed on previous therapies or for which no comparable alternative therapies are available.
- Rozlytrek as monotherapy is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options.
- Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced nonsmall cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
- Entrectinib is an oral selective inhibitor of the neurotrophic T receptor kinase (NTRK) and ROS1 that is used to treat solid tumors with NTRK gene fusion and non-small cell lung cancer with ROS1 mutations.
- Metastatic Non-Small Cell Lung Cancer
- Solid Metastatic Tumor
- Solid Tumors
In the US, entrectinib is indicated to treat patients whose cancers are ROS1-positive (have a specific genetic feature (biomarker)).[rx] It is to be used in those with solid tumors that:[rx]
- are caused by certain abnormal neurotrophic tyrosine receptor kinase (NTRK) genes, and
- have spread or if surgery to remove their cancer is likely to cause severe complications, and
- there is no acceptable treatment, or the cancer grew or spreads on other treatment
Entrectinib is not approved for use in those less than twelve years of age.
In the European Union, entrectinib as monotherapy is indicated for the treatment of adults and adolescents twelve years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,[rx]
- who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and[rx]
- who have not received a prior NTRK inhibitor[rx]
- who have no satisfactory treatment options?[rx]
It is also indicated for the treatment of adults with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.[rx]
Use in Cancer
Entrectinib is approved to treat:
- Non-small cell lung cancer that is ROS1 positive. It is used in adults whose cancer has metastasized (spread to other parts of the body).
- Solid tumors that have an NTRK gene fusion without a drug-resistance mutation in certain TRK proteins. It is used in adults and in children aged 12 years or older whose cancer has metastasized or cannot be removed by surgery and has gotten worse after other treatments or cannot be treated with other therapies.¹
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that entrectinib provides a clinical benefit in these patients.
Entrectinib is also being studied in the treatment of other types of cancer.
Contraindications
- low amount of magnesium in the blood
- low amount of calcium in the blood
- low amount of potassium in the blood
- chronic heart failure
- abnormal EKG with QT changes from birth
- liver problems
- high amount of uric acid in the blood
- pregnancy
- a patient who is producing milk and breastfeeding
Dosage
Strengths: 100 mg; 200 mg
Non-Small Cell Lung Cancer
- 600 mg orally once a day until disease progression or unacceptable toxicity
- For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive
Solid Tumors
- 600 mg orally once a day until disease progression or unacceptable toxicity
- For adult patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.
Pediatric Dose for Solid Tumors
12 years and older:
- Body surface area (BSA) greater than 1.5 m2: 600 mg orally once a day
- BSA 1.11 to 1.5 m2: 500 mg orally once a day
- BSA 0.91 to 1.1 m2: 400 mg orally once a day
Renal Dose Adjustments
- Mild or moderate renal impairment (CrCl 30 to less than 90 mL/min: No adjustment recommended.
- Severe renal impairment (CrCl greater than 30 mL/min): Data not available
Liver Dose Adjustments
- Grade 3 hepatic impairment: Withhold therapy until recovery to less than or equal to Grade 1 or baseline; resume at the same dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.
- Grade 4 hepatic impairment: Withhold therapy until recovery to less than or equal to Grade 1 or baseline; resume at a reduced dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue for recurrent Grade 4 events.
- ALT or AST greater than 3 times the upper limit of normal (ULN) with concurrent total bilirubin greater than 1.5 x ULN (in the absence of cholestasis or hemolysis): Permanently discontinue therapy.
Dose Adjustments
DOSE REDUCTIONS FOR ADVERSE REACTIONS:
FIRST DOSE REDUCTION:
- Adults and pediatric patients 12 years and older with BSA greater than 1.50 m2: 400 mg orally once daily
- Pediatric patients 12 years and older with BSA of 1.11 to 1.50 m2: 400 mg orally once daily
- Pediatric patients 12 years and older with BSA of 0.91 to 1.1 m2: 300 mg orally once daily
SECOND DOSE REDUCTION (if the patient cannot tolerate the second dose reduction permanently discontinue therapy):
- Adults and pediatric patients 12 years and older with BSA greater than 1.50 m2: 200 mg orally once daily
- Pediatric patients 12 years and older with BSA of 1.11 to 1.50 m2: 200 mg orally once daily
- Pediatric patients 12 years and older with BSA of 0.91 to 1.1 m2: 200 mg orally once daily
DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
CONGESTIVE HEART FAILURE:
- Grade 2 or 3: Withhold therapy until recovered to less than or equal to Grade 1; resume at a reduced dose.
- Grade 4: Permanently discontinue therapy.
CENTRAL NERVOUS SYSTEM EFFECTS:
- Intolerable Grade 2: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose or reduced dose.
- Grade 3: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose if resolution occurs within 4 weeks; permanently discontinue if the adverse reaction does not resolve within 4 weeks; resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.
- Grade 4: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose or reduced dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue therapy for recurrent Grade 4 events.
HYPERURICEMIA:
- QTc greater than 500 ms: Withhold therapy until QTc interval recovers to baseline; resume at the same dose if factors that cause QT prolongation are identified and corrected; resume at a reduced dose if other factors that cause QT prolongation are not identified.
- Torsade de Pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia: Permanently discontinue therapy.
VISION DISORDERS:
- Grade 2 or higher: Withhold therapy until improvement or stabilization; resume at the same dose or reduced dose as appropriate.
ANEMIA OR NEUTROPENIA:
- Grade 3 or 4: Withhold therapy until adverse reaction resolves or improves to recovery or improvement to Grade 1 or baseline; resume at the same or reduced dose, if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue for recurrent Grade 4 events.
DOSAGE MODIFICATIONS FOR DRUG INTERACTIONS: MODERATE AND STRONG CYP450 3A INHIBITORS:
Adults and pediatric patients 12 years and older with BSA Greater than 1.5 m2: Avoid coadministration of this drug with moderate or strong CYP450 3A inhibitors; if coadministration cannot be avoided, reduce the dose of this drug as follows:
- Moderate CYP450 3A Inhibitors: 200 mg orally once daily
- Strong CYP450 3A Inhibitors: 100 mg orally once daily
After discontinuation of a strong or moderate CYP450 3A inhibitor for 3 to 5 elimination half-lives, resume the dose that was taken prior to initiating the CYP450 3A inhibitor.
Administration advice:
- This drug may be taken with or without food.
- Swallow capsules whole do not open, crush, chew, or dissolve the contents of the capsule.
- If a dose is missed, take it as soon as it is remembered unless the next dose is due within 12 hours.
- If a patient vomits immediately after taking a dose, instruct them to repeat that dose.
Side Effects
The Most Common
- tiredness
- constipation
- diarrhea
- taste changes
- headache
- cough, fever, or other signs of infection
- muscle or joint pain
- back pain
- weight changes
- rash
- difficulty falling or staying asleep
- difficulty with learning, memory, attention, or problem solving
- mood changes such as anxiety, depression, confusion, or agitation
- bone pain or difficulty moving
- vision problems or changes in vision
- joint pain, stiffness, redness, or swelling
- pain in upper right part of the stomach, yellowing of skin or eyes, loss of appetite, or bleeding or bruising easily
- shortness of breath; difficulty breathing when lying down; or swelling of the arms, legs, hands, or feet
More common
- Abdominal or stomach pain or tenderness
- blurred vision
- burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feelings
- change in color vision
- clay-colored stools
- confusion
- dark urine
- decreased appetite
- defects in intelligence, short-term memory, learning ability, and attention
- difficulty seeing at night
- dizziness
- fever
- headache
- increased sensitivity of the eyes to sunlight
- itching or skin rash
- joint pain, stiffness, or swelling
- loss of appetite
- lower back, side, or stomach pain
- nausea and vomiting
- problems with balance
- sleepiness or unusual drowsiness
- swelling of the feet or lower legs
- trouble sleeping
- unusual tiredness or weakness
- yellow eyes or skin
Rare
- Chest pain
- decreased urine output
- dilated neck veins
- double vision
- extreme fatigue
- fainting
- irregular breathing
- irregular heartbeat recurrent
- loss of memory
- problems with memory
- problems with speech or speaking
- seeing double
- seeing, hearing, or feeling things that are not there
- swelling of the face, fingers, feet, or lower legs
- tightness in the chest
- trouble remembering
- troubled breathing
- weight gain
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Abaloparatide | The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Entrectinib. |
| Abametapir | The serum concentration of Entrectinib can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Entrectinib can be increased when combined with Abatacept. |
| Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Entrectinib. |
| Acalabrutinib | The metabolism of Entrectinib can be decreased when combined with Acalabrutinib. |
| Acebutolol | The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Entrectinib. |
| Acetaminophen | The metabolism of Entrectinib can be increased when combined with Acetaminophen. |
| Acetazolamide | The metabolism of Entrectinib can be decreased when combined with Acetazolamide. |
| Acrivastine | The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Entrectinib. |
| Adalimumab | The metabolism of Entrectinib can be increased when combined with Adalimumab. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Entrectinib. |
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Entrectinib. |
| Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Entrectinib. |
| Albendazole | The metabolism of Entrectinib can be decreased when combined with Albendazole. |
| Aldesleukin | The metabolism of Entrectinib can be decreased when combined with Aldesleukin. |
| Alfuzosin | The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Entrectinib. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Entrectinib. |
| Alpelisib | The metabolism of Entrectinib can be increased when combined with Alpelisib. |
| Amantadine | The risk or severity of QTc prolongation can be increased when Amantadine is combined with Entrectinib. |
| Ambrisentan | The serum concentration of Ambrisentan can be increased when it is combined with Entrectinib. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Entrectinib. |
| Aminoglutethimide | The metabolism of Entrectinib can be increased when combined with Aminoglutethimide. |
| Amiodarone | The metabolism of Entrectinib can be decreased when combined with Amiodarone. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Entrectinib. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Entrectinib. |
| Amlodipine | The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Entrectinib. |
| Amobarbital | The metabolism of Entrectinib can be increased when combined with Amobarbital. |
| Amodiaquine | The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Entrectinib. |
| Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Entrectinib. |
| Amprenavir | The metabolism of Entrectinib can be increased when combined with Amprenavir. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Entrectinib. |
| Anakinra | The metabolism of Entrectinib can be increased when combined with Anakinra. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Antazoline is combined with Entrectinib. |
| Apalutamide | The metabolism of Entrectinib can be increased when combined with Apalutamide. |
| Apixaban | The serum concentration of Apixaban can be increased when it is combined with Entrectinib. |
| Apomorphine | The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Entrectinib. |
| Apremilast | The metabolism of Entrectinib can be increased when combined with Apremilast. |
| Aprepitant | The metabolism of Entrectinib can be decreased when combined with Aprepitant. |
| Arformoterol | The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Entrectinib. |
| Aripiprazole | The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Entrectinib. |
| Aripiprazole | The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Entrectinib. |
| Armodafinil | The metabolism of Entrectinib can be increased when combined with Armodafinil. |
| Arsenic trioxide | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Entrectinib. |
| Artemether | The risk or severity of QTc prolongation can be increased when Artemether is combined with Entrectinib. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Articaine. |
| Asciminib | The serum concentration of Entrectinib can be increased when it is combined with Asciminib. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Asenapine is combined with Entrectinib. |
| Astemizole | The risk or severity of QTc prolongation can be increased when Astemizole is combined with Entrectinib. |
| Asunaprevir | The metabolism of Entrectinib can be increased when combined with Asunaprevir. |
| Atazanavir | The metabolism of Entrectinib can be decreased when combined with Atazanavir. |
| Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Entrectinib. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Entrectinib. |
| Avacopan | The metabolism of Entrectinib can be decreased when combined with Avacopan. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Entrectinib. |
| Avatrombopag | The serum concentration of Avatrombopag can be increased when it is combined with Entrectinib. |
| Axitinib | The serum concentration of Axitinib can be increased when it is combined with Entrectinib. |
| Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Entrectinib. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Entrectinib. |
| Beclomethasone | The metabolism of Entrectinib can be increased when combined with Beclomethasone dipropionate. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Entrectinib. |
| Belantamab | The serum concentration of Belantamab mafodotin can be increased when it is combined with Entrectinib. |
| Belinostat | The serum concentration of Belinostat can be increased when it is combined with Entrectinib. |
| Belzutifan | The serum concentration of Entrectinib can be decreased when it is combined with Belzutifan. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Entrectinib. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Entrectinib. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Benzyl alcohol. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Bepridil is combined with Entrectinib. |
| Berotralstat | The metabolism of Entrectinib can be decreased when combined with Berotralstat. |
| Betamethasone | The metabolism of Entrectinib can be increased when combined with Betamethasone. |
| Betamethasone | The metabolism of Entrectinib can be increased when combined with Betamethasone phosphate. |
| Betaxolol | The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Entrectinib. |
| Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Entrectinib. |
| Bexarotene | The metabolism of Entrectinib can be increased when combined with Bexarotene. |
| Bicalutamide | The metabolism of Entrectinib can be decreased when combined with Bicalutamide. |
| Bifonazole | The metabolism of Entrectinib can be decreased when combined with Bifonazole. |
| Bilastine | The risk or severity of QTc prolongation can be increased when Bilastine is combined with Entrectinib. |
| Bimekizumab | The metabolism of Entrectinib can be increased when combined with Bimekizumab. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Entrectinib. |
| Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with Entrectinib. |
| Boceprevir | The metabolism of Entrectinib can be decreased when combined with Boceprevir. |
| Bortezomib | The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Entrectinib. |
| Bosentan | The metabolism of Entrectinib can be increased when combined with Bosentan. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Entrectinib. |
| Brentuximab | The serum concentration of Brentuximab vedotin can be increased when it is combined with Entrectinib. |
| Bretylium | The risk or severity of QTc prolongation can be increased when Bretylium is combined with Entrectinib. |
| Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Entrectinib. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Entrectinib. |
| Budesonide | The metabolism of Entrectinib can be increased when combined with Budesonide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Bupivacaine. |
| Buprenorphine | The metabolism of Entrectinib can be decreased when combined with Buprenorphine. |
| Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Entrectinib. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Butacaine. |
| Butalbital | The metabolism of Entrectinib can be increased when combined with Butalbital. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Butamben. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Entrectinib. |
| Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Entrectinib. |
| Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Entrectinib. |
| Calcitriol | The metabolism of Entrectinib can be increased when combined with Calcitriol. |
| Canagliflozin | The serum concentration of Canagliflozin can be increased when it is combined with Entrectinib. |
| Canakinumab | The metabolism of Entrectinib can be increased when combined with Canakinumab. |
| Candicidin | The metabolism of Entrectinib can be decreased when combined with Candicidin. |
| Cannabidiol | The metabolism of Entrectinib can be decreased when combined with Cannabidiol. |
| Capsaicin | The metabolism of Entrectinib can be decreased when combined with Capsaicin. |
| Carbamazepine | The metabolism of Entrectinib can be increased when combined with Carbamazepine. |
| Carbimazole | The therapeutic efficacy of Carbimazole can be decreased when used in combination with Entrectinib. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Entrectinib. |
| Carfilzomib | The serum concentration of Carfilzomib can be increased when it is combined with Entrectinib. |
| Cefradine | The metabolism of Entrectinib can be increased when combined with Cefradine. |
| Celiprolol | The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Entrectinib. |
| Cenobamate | The metabolism of Entrectinib can be increased when combined with Cenobamate. |
| Cephalexin | The metabolism of Entrectinib can be decreased when combined with Cephalexin. |
| Ceritinib | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Entrectinib. |
| Cerivastatin | The metabolism of Entrectinib can be increased when combined with Cerivastatin. |
| Certolizumab pegol | The metabolism of Entrectinib can be increased when combined with Certolizumab pegol. |
| Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Entrectinib. |
| Chloramphenicol | The metabolism of Entrectinib can be decreased when combined with Chloramphenicol. |
| Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Entrectinib. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Chloroprocaine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Entrectinib. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Entrectinib. |
| Chlorpromazine | The metabolism of Entrectinib can be increased when combined with Chlorpromazine. |
| Chlorprothixene | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Entrectinib. |
| Cilostazol | The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Entrectinib. |
| Cimetidine | The metabolism of Entrectinib can be decreased when combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Cinchocaine. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Entrectinib. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Entrectinib. |
| Ciprofloxacin | The metabolism of Entrectinib can be decreased when combined with Ciprofloxacin. |
| Cisapride | The risk or severity of QTc prolongation can be increased when Cisapride is combined with Entrectinib. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Citalopram is combined with Entrectinib. |
| Clarithromycin | The metabolism of Entrectinib can be decreased when combined with Clarithromycin. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Clemastine is combined with Entrectinib. |
| Clevidipine | The metabolism of Entrectinib can be increased when combined with Clevidipine. |
| Clobazam | The metabolism of Entrectinib can be increased when combined with Clobazam. |
| Clobetasol | The metabolism of Entrectinib can be increased when combined with Clobetasol propionate. |
| Clofazimine | The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Entrectinib. |
| Clofibrate | The metabolism of Entrectinib can be increased when combined with Clofibrate. |
| Clomifene | The serum concentration of Clomifene can be increased when it is combined with Entrectinib. |
| Clomipramine | The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Entrectinib. |
| Clozapine | The metabolism of Entrectinib can be increased when combined with Clozapine. |
| Cobicistat | The metabolism of Entrectinib can be decreased when combined with Cobicistat. |
| Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Entrectinib. |
| Cocaine | The risk or severity of QTc prolongation can be increased when Cocaine is combined with Entrectinib. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Entrectinib. |
| Conivaptan | The metabolism of Entrectinib can be decreased when combined with Conivaptan. |
| Copanlisib | The serum concentration of Copanlisib can be increased when it is combined with Entrectinib. |
| Corticotropin | The metabolism of Entrectinib can be increased when combined with Corticotropin. |
| Cortisone acetate | The metabolism of Entrectinib can be increased when combined with Cortisone acetate. |
| Crizotinib | The metabolism of Entrectinib can be decreased when combined with Crizotinib. |
| Curcumin | The metabolism of Entrectinib can be decreased when combined with Curcumin. |
| Cyclizine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Entrectinib. |
| Cyclophosphamide | The metabolism of Entrectinib can be increased when combined with Cyclophosphamide. |
| Cyclosporine | The metabolism of Entrectinib can be decreased when combined with Cyclosporine. |
| Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Entrectinib. |
| Cyproterone acetate | The metabolism of Entrectinib can be decreased when combined with Cyproterone acetate. |
| Dabigatran etexilate | The serum concentration of Dabigatran etexilate can be increased when it is combined with Entrectinib. |
| Dabrafenib | The metabolism of Entrectinib can be increased when combined with Dabrafenib. |
| Dacomitinib | The serum concentration of Dacomitinib can be increased when it is combined with Entrectinib. |
| Dactinomycin | The serum concentration of Dactinomycin can be increased when it is combined with Entrectinib. |
| Dalfopristin | The metabolism of Entrectinib can be decreased when combined with Dalfopristin. |
| Danazol | The metabolism of Entrectinib can be decreased when combined with Danazol. |
| Daptomycin | The serum concentration of Daptomycin can be increased when it is combined with Entrectinib. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Entrectinib. |
| Darolutamide | The serum concentration of Darolutamide can be increased when it is combined with Entrectinib. |
| Darunavir | The metabolism of Entrectinib can be decreased when combined with Darunavir. |
| Dasabuvir | The serum concentration of Dasabuvir can be increased when it is combined with Entrectinib. |
| Dasatinib | The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Entrectinib. |
| Daunorubicin | The metabolism of Entrectinib can be decreased when combined with Daunorubicin. |
| Deferasirox | The metabolism of Entrectinib can be increased when combined with Deferasirox. |
| Deflazacort | The metabolism of Entrectinib can be increased when combined with Deflazacort. |
| Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Entrectinib. |
| Delafloxacin | The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Entrectinib. |
| Delamanid | The risk or severity of QTc prolongation can be increased when Delamanid is combined with Entrectinib. |
| Delavirdine | The metabolism of Entrectinib can be decreased when combined with Delavirdine. |
| Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Entrectinib. |
| Desipramine | The risk or severity of QTc prolongation can be increased when Desipramine is combined with Entrectinib. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Entrectinib. |
| Desvenlafaxine | The metabolism of Entrectinib can be decreased when combined with Desvenlafaxine. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Deutetrabenazine is combined with Entrectinib. |
| Dexamethasone | The metabolism of Entrectinib can be increased when combined with Dexamethasone. |
| Dexamethasone | The metabolism of Entrectinib can be increased when combined with Dexamethasone acetate. |
| Dexbrompheniramine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Entrectinib. |
| Dexchlorphenir | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Entrectinib. |
| Dextropropoxyphene | The metabolism of Entrectinib can be decreased when combined with Dextropropoxyphene. |
| Dicloxacillin | The metabolism of Entrectinib can be increased when combined with Dicloxacillin. |
| Diethylstilbestrol | The metabolism of Entrectinib can be decreased when combined with Diethylstilbestrol. |
| Difluocortolone | The metabolism of Entrectinib can be increased when combined with Difluocortolone. |
| Digitoxin | The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Entrectinib. |
| Digoxin | The risk or severity of QTc prolongation can be increased when Digoxin is combined with Entrectinib. |
| Dihydroergocornine | The metabolism of Entrectinib can be decreased when combined with Dihydroergocornine. |
| Dihydroergocristine | The metabolism of Entrectinib can be decreased when combined with Dihydroergocristine. |
| Dihydroergotamine | The metabolism of Entrectinib can be decreased when combined with Dihydroergotamine. |
| Diltiazem | The metabolism of Entrectinib can be decreased when combined with Diltiazem. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Entrectinib. |
| Dimethyl sulfoxide | The metabolism of Entrectinib can be decreased when combined with Dimethyl sulfoxide. |
| Diosmin | The metabolism of Entrectinib can be decreased when combined with Diosmin. |
| Diphenhydramine | The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Entrectinib. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Entrectinib. |
| Disulfiram | The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Entrectinib. |
| Docetaxel | The metabolism of Entrectinib can be decreased when combined with Docetaxel. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Entrectinib. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Entrectinib. |
| Dolutegravir | The serum concentration of Dolutegravir can be increased when it is combined with Entrectinib. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Domperidone is combined with Entrectinib. |
| Dosulepin | The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Entrectinib. |
| Doxazosin | The metabolism of Entrectinib can be decreased when combined with Doxazosin. |
| Doxepin | The risk or severity of QTc prolongation can be increased when Doxepin is combined with Entrectinib. |
| Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Entrectinib. |
| Doxylamine | The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Entrectinib. |
| Dronedarone | The metabolism of Entrectinib can be decreased when combined with Dronedarone. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Entrectinib. |
| Drospirenone | The metabolism of Entrectinib can be decreased when combined with Drospirenone. |
| Duvelisib | The metabolism of Entrectinib can be decreased when combined with Duvelisib. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Dyclonine. |
| Ebastine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Entrectinib. |
| Echinacea | The metabolism of Entrectinib can be increased when combined with Echinacea. |
| Econazole | The metabolism of Entrectinib can be decreased when combined with Econazole. |
| Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Entrectinib. |
| Efavirenz | The metabolism of Entrectinib can be increased when combined with Efavirenz. |
| Elagolix | The serum concentration of Elagolix can be increased when it is combined with Entrectinib. |
| Elbasvir | The serum concentration of Elbasvir can be increased when it is combined with Entrectinib. |
| Elexacaftor | The metabolism of Entrectinib can be decreased when combined with Elexacaftor. |
| Eliglustat | The risk or severity of QTc prolongation can be increased when Eliglustat is combined with Entrectinib. |
| Elvitegravir | The metabolism of Entrectinib can be decreased when combined with Elvitegravir. |
| Emapalumab | The metabolism of Entrectinib can be increased when combined with Emapalumab. |
| Emedastine | The risk or severity of QTc prolongation can be increased when Emedastine is combined with Entrectinib. |
| Enasidenib | The metabolism of Entrectinib can be increased when combined with Enasidenib. |
| Encainide | The risk or severity of QTc prolongation can be increased when Encainide is combined with Entrectinib. |
| Encorafenib | The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Entrectinib. |
| Enfortumab | The serum concentration of Enfortumab vedotin can be increased when it is combined with Entrectinib. |
| Enoxacin | The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Entrectinib. |
| Enzalutamide | The metabolism of Entrectinib can be increased when combined with Enzalutamide. |
| Epinastine | The risk or severity of QTc prolongation can be increased when Epinastine is combined with Entrectinib. |
| Epinephrine | The metabolism of Entrectinib can be decreased when combined with Epinephrine. |
| Ergotamine | The metabolism of Entrectinib can be decreased when combined with Ergotamine. |
| Eribulin | The risk or severity of QTc prolongation can be increased when Eribulin is combined with Entrectinib. |
| Erlotinib | The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Entrectinib. |
| Ertugliflozin | The serum concentration of Ertugliflozin can be increased when it is combined with Entrectinib. |
| Erythromycin | The metabolism of Entrectinib can be decreased when combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Entrectinib. |
| Escitalopram | The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Entrectinib. |
| Esketamine | The metabolism of Entrectinib can be increased when combined with Esketamine. |
| Eslicarbazepine | The metabolism of Entrectinib can be increased when combined with Eslicarbazepine. |
| Eslicarbazepine | The metabolism of Entrectinib can be increased when combined with Eslicarbazepine acetate. |
| Esmolol | The risk or severity of QTc prolongation can be increased when Esmolol is combined with Entrectinib. |
| Estetrol | The metabolism of Entrectinib can be decreased when combined with Estetrol. |
| Estradiol acetate | The metabolism of Entrectinib can be increased when combined with Estradiol acetate. |
| Estradiol benzoate | The metabolism of Entrectinib can be increased when combined with Estradiol benzoate. |
| Estradiol cypionate | The metabolism of Entrectinib can be increased when combined with Estradiol cypionate. |
| Estradiol dienanthate | The metabolism of Entrectinib can be increased when combined with Estradiol dienanthate. |
| Estradiol valerate | The metabolism of Entrectinib can be increased when combined with Estradiol valerate. |
| Etanercept | The metabolism of Entrectinib can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Entrectinib can be decreased when combined with Ethambutol. |
| Ethanol | The metabolism of Entrectinib can be increased when combined with Ethanol. |
| Ethosuximide | The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Entrectinib. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Etidocaine. |
| Etoposide | The serum concentration of Etoposide can be increased when it is combined with Entrectinib. |
| Etoricoxib | The metabolism of Entrectinib can be decreased when combined with Etoricoxib. |
| Etravirine | The metabolism of Entrectinib can be increased when combined with Etravirine. |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with Entrectinib. |
| Ezogabine | The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Entrectinib. |
| Famotidine | The risk or severity of QTc prolongation can be increased when Famotidine is combined with Entrectinib. |
| Fedratinib | The serum concentration of Fedratinib can be increased when it is combined with Entrectinib. |
| Felbamate | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Entrectinib. |
| Felodipine | The risk or severity of QTc prolongation can be increased when Felodipine is combined with Entrectinib. |
| Fenofibrate | The metabolism of Entrectinib can be decreased when combined with Fenofibrate. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Entrectinib is combined with Fexinidazole. |
| Fexofenadine | The serum concentration of Fexofenadine can be increased when it is combined with Entrectinib. |
| Flecainide | The risk or severity of QTc prolongation can be increased when Flecainide is combined with Entrectinib. |
| Flucloxacillin | The metabolism of Entrectinib can be increased when combined with Flucloxacillin. |
| Fluconazole | The metabolism of Entrectinib can be decreased when combined with Fluconazole. |
| Flunisolide | The metabolism of Entrectinib can be increased when combined with Flunisolide. |
| Fluocinolone | The metabolism of Entrectinib can be increased when combined with Fluocinolone acetonide. |
| Fluocinonide | The metabolism of Entrectinib can be increased when combined with Fluocinonide. |
| Fluocortolone | The metabolism of Entrectinib can be increased when combined with Fluocortolone. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Entrectinib. |
| Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Entrectinib. |
| Flupentixol | The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Entrectinib. |
| Fluspirilene | The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Entrectinib. |
| Fluticasone | The metabolism of Entrectinib can be increased when combined with Fluticasone. |
| Fluticasone furoate | The metabolism of Entrectinib can be increased when combined with Fluticasone furoate. |
| Fluticasone | The metabolism of Entrectinib can be decreased when combined with Fluticasone propionate. |
| Fluvoxamine | The metabolism of Entrectinib can be decreased when combined with Fluvoxamine. |
| Follitropin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Entrectinib. |
| Formestane | The metabolism of Entrectinib can be increased when combined with Formestane. |
| Formoterol | The risk or severity of QTc prolongation can be increased when Formoterol is combined with Entrectinib. |
| Fosamprenavir | The metabolism of Entrectinib can be decreased when combined with Fosamprenavir. |
| Fosaprepitant | The metabolism of Entrectinib can be increased when combined with Fosaprepitant. |
| Foscarnet | The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Entrectinib. |
| Fosnetupitant | The metabolism of Entrectinib can be decreased when combined with Fosnetupitant. |
| Fosphenytoin | The metabolism of Entrectinib can be increased when combined with Fosphenytoin. |
| Fostamatinib | The metabolism of Entrectinib can be decreased when combined with Fostamatinib. |
| Fostemsavir | The serum concentration of Fostemsavir can be increased when it is combined with Entrectinib. |
| Fusidic acid | The metabolism of Entrectinib can be decreased when combined with Fusidic acid. |
| Futibatinib | The serum concentration of Futibatinib can be increased when it is combined with Entrectinib. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Entrectinib. |
| Galantamine | The risk or severity of QTc prolongation can be increased when Galantamine is combined with Entrectinib. |
| Gatifloxacin | The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Entrectinib. |
| Gemcitabine | The serum concentration of Gemcitabine can be increased when it is combined with Entrectinib. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Entrectinib. |
| Gilteritinib | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Entrectinib. |
| Ginkgo biloba | The metabolism of Entrectinib can be decreased when combined with Ginkgo biloba. |
| Glasdegib | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Entrectinib. |
| Glecaprevir | The metabolism of Entrectinib can be decreased when combined with Glecaprevir. |
| Glyburide | The metabolism of Entrectinib can be decreased when combined with Glyburide. |
| Glycerol | The metabolism of Entrectinib can be increased when combined with Glycerol phenylbutyrate. |
| Golimumab | The metabolism of Entrectinib can be increased when combined with Golimumab. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Entrectinib. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Granisetron is combined with Entrectinib. |
| Grazoprevir | The serum concentration of Grazoprevir can be increased when it is combined with Entrectinib. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Entrectinib. |
| Griseofulvin | The metabolism of Entrectinib can be increased when combined with Griseofulvin. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Entrectinib. |
| Haloperidol | The metabolism of Entrectinib can be decreased when combined with Haloperidol. |
| Histrelin | The risk or severity of QTc prolongation can be increased when Histrelin is combined with Entrectinib. |
| Hydralazine | The metabolism of Entrectinib can be decreased when combined with Hydralazine. |
| Hydrochlorothiazide | The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Entrectinib. |
| Hydrocortamate | The metabolism of Entrectinib can be increased when combined with Hydrocortamate. |
| Hydrocortisone | The metabolism of Entrectinib can be increased when combined with Hydrocortisone. |
| Hydrocortisone | The metabolism of Entrectinib can be increased when combined with Hydrocortisone acetate. |
| Hydrocortisone | The metabolism of Entrectinib can be increased when combined with Hydrocortisone butyrate. |
| Hydrocortisone | The metabolism of Entrectinib can be increased when combined with Hydrocortisone succinate. |
| Hydroxychloroquine | The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Entrectinib. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Entrectinib is combined with Hydroxyzine. |
| Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Entrectinib. |
| Ibandronate | The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Entrectinib. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Entrectinib. |
| Idelalisib | The metabolism of Entrectinib can be decreased when combined with Idelalisib. |
| Ifosfamide | The metabolism of Entrectinib can be increased when combined with Ifosfamide. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Entrectinib. |
| Imatinib | The risk or severity of QTc prolongation can be increased when Imatinib is combined with Entrectinib. |
| Imipramine | The risk or severity of QTc prolongation can be increased when Imipramine is combined with Entrectinib. |
| Indacaterol | The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Entrectinib. |
| Indapamide | The risk or severity of QTc prolongation can be increased when Indapamide is combined with Entrectinib. |
| Indinavir | The metabolism of Entrectinib can be decreased when combined with Indinavir. |
| Infigratinib | The metabolism of Entrectinib can be decreased when combined with Infigratinib. |
| Infliximab | The metabolism of Entrectinib can be increased when combined with Infliximab. |
| Inotersen | The risk or severity of QTc prolongation can be increased when Inotersen is combined with Entrectinib. |
| Inotuzumab | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Entrectinib. |
| Irbesartan | The metabolism of Entrectinib can be decreased when combined with Irbesartan. |
| Isavuconazole | The metabolism of Entrectinib can be decreased when combined with Isavuconazole. |
| Isavuconazonium | The metabolism of Entrectinib can be increased when combined with Isavuconazonium. |
| Isoflurane | The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Entrectinib. |
| Isoniazid | The metabolism of Entrectinib can be decreased when combined with Isoniazid. |
| Isradipine | The metabolism of Entrectinib can be decreased when combined with Isradipine. |
| Itraconazole | The metabolism of Entrectinib can be decreased when combined with Itraconazole. |
| Ivabradine | The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Entrectinib. |
| Ivacaftor | The metabolism of Entrectinib can be decreased when combined with Ivacaftor. |
| Ivosidenib | The metabolism of Entrectinib can be increased when combined with Ivosidenib. |
| Ketazolam | The metabolism of Entrectinib can be decreased when combined with Ketazolam. |
| Ketoconazole | The metabolism of Entrectinib can be decreased when combined with Ketoconazole. |
| Lacidipine | The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Entrectinib. |
| Lacosamide | The metabolism of Entrectinib can be decreased when combined with Lacosamide. |
| Lamotrigine | The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Entrectinib. |
| Lanreotide | The metabolism of Entrectinib can be decreased when combined with Lanreotide. |
| Lapatinib | The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Entrectinib. |
| Larotrectinib | The serum concentration of Larotrectinib can be increased when it is combined with Entrectinib. |
| Lasmiditan | The serum concentration of Lasmiditan can be increased when it is combined with Entrectinib. |
| Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Entrectinib. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Entrectinib. |
| Lemborexant | The serum concentration of Lemborexant can be increased when it is combined with Entrectinib. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Entrectinib. |
| Lesinurad | The metabolism of Entrectinib can be increased when combined with Lesinurad. |
| Letermovir | The metabolism of Entrectinib can be decreased when combined with Letermovir. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Entrectinib. |
| Levacetylmethadol | The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Entrectinib. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Levobupivacaine. |
| Levocabastine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Entrectinib. |
| Levocetirizine | The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Entrectinib. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Entrectinib. |
| Levoketoconazole | The metabolism of Entrectinib can be decreased when combined with Levoketoconazole. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Entrectinib. |
| Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Entrectinib. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Lidocaine. |
| Lidoflazine | The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Entrectinib. |
| Linagliptin | The metabolism of Entrectinib can be decreased when combined with Linagliptin. |
| Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with Entrectinib. |
| Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with Entrectinib. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Entrectinib. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Entrectinib. |
| Lomitapide | The metabolism of Entrectinib can be decreased when combined with Lomitapide. |
| Lonafarnib | The metabolism of Entrectinib can be decreased when combined with Lonafarnib. |
| Loncastuximab | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Entrectinib. |
| Loperamide | The risk or severity of QTc prolongation can be increased when Loperamide is combined with Entrectinib. |
| Lopinavir | The metabolism of Entrectinib can be decreased when combined with Lopinavir. |
| Lorlatinib | The metabolism of Entrectinib can be increased when combined with Lorlatinib. |
| Losartan | The risk or severity of QTc prolongation can be increased when Losartan is combined with Entrectinib. |
| Lovastatin | The metabolism of Entrectinib can be decreased when combined with Lovastatin. |
| Lumacaftor | The metabolism of Entrectinib can be increased when combined with Lumacaftor. |
| Lumefantrine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Entrectinib. |
| Lurasidone | The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Entrectinib. |
| Lusutrombopag | The serum concentration of Lusutrombopag can be increased when it is combined with Entrectinib. |
| Macimorelin | The risk or severity of QTc prolongation can be increased when Macimorelin is combined with Entrectinib. |
| Manidipine | The metabolism of Entrectinib can be decreased when combined with Manidipine. |
| Mannitol | The serum concentration of Mannitol can be increased when it is combined with Entrectinib. |
| Maprotiline | The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Entrectinib. |
| Mavacamten | The metabolism of Entrectinib can be increased when combined with Mavacamten. |
| Mefloquine | The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Entrectinib. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Meloxicam. |
| Meperidine | The metabolism of Entrectinib can be decreased when combined with Meperidine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Mepivacaine. |
| Meprednisone | The metabolism of Entrectinib can be increased when combined with Meprednisone. |
| Mepyramine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Entrectinib. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Entrectinib. |
| Methadone | The risk or severity of QTc prolongation can be increased when Methadone is combined with Entrectinib. |
| Methimazole | The metabolism of Entrectinib can be decreased when combined with Methimazole. |
| Methotrimeprazine | The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Entrectinib. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Entrectinib. |
| Methsuximide | The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Entrectinib. |
| Methylene blue | The metabolism of Entrectinib can be decreased when combined with Methylene blue. |
| Methylergometrine | The metabolism of Entrectinib can be decreased when combined with Methylergometrine. |
| Methylphenobarbital | The metabolism of Entrectinib can be increased when combined with Methylphenobarbital. |
| Methylprednisolone | The metabolism of Entrectinib can be increased when combined with Methylprednisolone. |
| Methylprednisone | The metabolism of Entrectinib can be decreased when combined with Methylprednisone. |
| Methysergide | The metabolism of Entrectinib can be decreased when combined with Methysergide. |
| Metoclopramide | The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Entrectinib. |
| Metreleptin | The metabolism of Entrectinib can be increased when combined with Metreleptin. |
| Metronidazole | The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Entrectinib. |
| Metyrapone | The metabolism of Entrectinib can be increased when combined with Metyrapone. |
| Miconazole | The metabolism of Entrectinib can be decreased when combined with Miconazole. |
| Midazolam | The metabolism of Entrectinib can be decreased when combined with Midazolam. |
| Midostaurin | The metabolism of Entrectinib can be increased when combined with Midostaurin. |
| Mifepristone | The metabolism of Entrectinib can be increased when combined with Mifepristone. |
| Milnacipran | The metabolism of Entrectinib can be decreased when combined with Milnacipran. |
| Miocamycin | The metabolism of Entrectinib can be decreased when combined with Miocamycin. |
| Mirabegron | The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Entrectinib. |
| Mirtazapine | The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Entrectinib. |
| Mitapivat | The metabolism of Entrectinib can be increased when combined with Mitapivat. |
| Mitotane | The metabolism of Entrectinib can be increased when combined with Mitotane. |
| Mizolastine | The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Entrectinib. |
| Mobocertinib | The risk or severity of QTc prolongation can be increased when Entrectinib is combined with Mobocertinib. |
| Modafinil | The metabolism of Entrectinib can be increased when combined with Modafinil. |
| Moexipril | The risk or severity of QTc prolongation can be increased when Moexipril is combined with Entrectinib. |
| Mometasone | The metabolism of Entrectinib can be increased when combined with Mometasone furoate. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Moricizine is combined with Entrectinib. |
| Morphine | The serum concentration of Morphine can be increased when it is combined with Entrectinib. |
| Mosunetuzumab | The metabolism of Entrectinib can be decreased when combined with Mosunetuzumab. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Entrectinib. |
| Nafcillin | The metabolism of Entrectinib can be increased when combined with Nafcillin. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Entrectinib. |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Entrectinib. |
| Naloxone | The metabolism of Entrectinib can be decreased when combined with Naloxone. |
| Nefazodone | The metabolism of Entrectinib can be decreased when combined with Nefazodone. |
| Nelfinavir | The metabolism of Entrectinib can be decreased when combined with Nelfinavir. |
| Netupitant | The metabolism of Entrectinib can be decreased when combined with Netupitant. |
| Niacin | The metabolism of Entrectinib can be decreased when combined with Niacin. |
| Nicardipine | The metabolism of Entrectinib can be decreased when combined with Nicardipine. |
| Nifedipine | The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Entrectinib. |
| Nilotinib | The metabolism of Entrectinib can be decreased when combined with Nilotinib. |
| Nilvadipine | The metabolism of Entrectinib can be decreased when combined with Nilvadipine. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Entrectinib. |
| Nintedanib | The metabolism of Entrectinib can be decreased when combined with Nintedanib. |
| Nitrendipine | The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Entrectinib. |
| Norethisterone | The metabolism of Entrectinib can be decreased when combined with Norethisterone. |
| Norfloxacin | The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Entrectinib. |
| Norgestimate | The metabolism of Entrectinib can be increased when combined with Norgestimate. |
| Nortriptyline | The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Entrectinib. |
| Noscapine | The metabolism of Entrectinib can be decreased when combined with Noscapine. |
| Octreotide | The risk or severity of QTc prolongation can be increased when Octreotide is combined with Entrectinib. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Entrectinib. |
| Olanzapine | The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Entrectinib. |
| Olaparib | The metabolism of Entrectinib can be decreased when combined with Olaparib. |
| Olodaterol | The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Entrectinib. |
| Omadacycline | The serum concentration of Omadacycline can be increased when it is combined with Entrectinib. |
| Ombitasvir | The serum concentration of Ombitasvir can be increased when it is combined with Entrectinib. |
| Omeprazole | The metabolism of Entrectinib can be increased when combined with Omeprazole. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Entrectinib. |
| Oritavancin | The metabolism of Entrectinib can be increased when combined with Oritavancin. |
| Orphenadrine | The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Entrectinib. |
| Osilodrostat | The metabolism of Entrectinib can be decreased when combined with Osilodrostat. |
| Osimertinib | The serum concentration of Osimertinib can be increased when it is combined with Entrectinib. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Entrectinib. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Entrectinib. |
| Oxcarbazepine | The metabolism of Entrectinib can be increased when combined with Oxcarbazepine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Oxetacaine. |
| Oxprenolol | The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Entrectinib. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Oxybuprocaine. |
| Oxybutynin | The metabolism of Entrectinib can be decreased when combined with Oxybutynin. |
| Oxytocin | The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entrectinib. |
| Paclitaxel | The metabolism of Entrectinib can be increased when combined with Paclitaxel. |
| Pacritinib | The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Entrectinib. |
| Palbociclib | The metabolism of Entrectinib can be decreased when combined with Palbociclib. |
| Paliperidone | The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Entrectinib. |
| Panobinostat | The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Entrectinib. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Papaverine is combined with Entrectinib. |
| Parathyroid | The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Entrectinib. |
| Paritaprevir | The serum concentration of Paritaprevir can be increased when it is combined with Entrectinib. |
| Pasireotide | The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Entrectinib. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Entrectinib. |
| Pefloxacin | The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Entrectinib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Entrectinib. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Entrectinib. |
| Pentobarbital | The metabolism of Entrectinib can be increased when combined with Pentobarbital. |
| Perampanel | The metabolism of Entrectinib can be increased when combined with Perampanel. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Entrectinib. |
| Perhexiline | The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Entrectinib. |
| Pheniramine | The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Entrectinib. |
| Phenobarbital | The metabolism of Entrectinib can be increased when combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Phenol. |
| Phenylbutazone | The metabolism of Entrectinib can be increased when combined with Phenylbutazone. |
| Phenytoin | The metabolism of Entrectinib can be increased when combined with Phenytoin. |
| Pibrentasvir | The serum concentration of Pibrentasvir can be increased when it is combined with Entrectinib. |
| Pimavanserin | The metabolism of Entrectinib can be decreased when combined with Pimavanserin. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Pimozide is combined with Entrectinib. |
| Pinaverium | The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Entrectinib. |
| Piperaquine | The metabolism of Entrectinib can be decreased when combined with Piperaquine. |
| Pitolisant | The metabolism of Entrectinib can be increased when combined with Pitolisant. |
| Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Entrectinib. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Entrectinib. |
| Posaconazole | The metabolism of Entrectinib can be decreased when combined with Posaconazole. |
| Potassium Iodide | The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Entrectinib. |
| Potassium | The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Entrectinib. |
| Pralsetinib | The metabolism of Entrectinib can be increased when combined with Pralsetinib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Pramocaine. |
| Pravastatin | The serum concentration of Pravastatin can be increased when it is combined with Entrectinib. |
| Prednisolone | The metabolism of Entrectinib can be increased when combined with Prednisolone. |
| Prednisolone acet | The metabolism of Entrectinib can be increased when combined with Prednisolone acetate. |
| Prednisolone | The metabolism of Entrectinib can be increased when combined with Prednisolone phosphate. |
| Prednisone | The metabolism of Entrectinib can be increased when combined with Prednisone acetate. |
| Pregabalin | The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Entrectinib. |
| Prenylamine | The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Entrectinib. |
| Pretomanid | The metabolism of Entrectinib can be decreased when combined with Pretomanid. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Prilocaine. |
| Primaquine | The metabolism of Entrectinib can be decreased when combined with Primaquine. |
| Primidone | The metabolism of Entrectinib can be increased when combined with Primidone. |
| Probenecid | The metabolism of Entrectinib can be increased when combined with Probenecid. |
| Probucol | The risk or severity of QTc prolongation can be increased when Probucol is combined with Entrectinib. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Procainamide is combined with Entrectinib. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Procaine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Entrectinib. |
| Promazine | The risk or severity of QTc prolongation can be increased when Promazine is combined with Entrectinib. |
| Promethazine | The risk or severity of QTc prolongation can be increased when Promethazine is combined with Entrectinib. |
| Propafenone | The risk or severity of QTc prolongation can be increased when Propafenone is combined with Entrectinib. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Proparacaine. |
| Propofol | The risk or severity of QTc prolongation can be increased when Propofol is combined with Entrectinib. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Propoxycaine. |
| Propranolol | The risk or severity of QTc prolongation can be increased when Propranolol is combined with Entrectinib. |
| Propylthiouracil | The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Entrectinib. |
| Protirelin | The therapeutic efficacy of Protirelin can be decreased when used in combination with Entrectinib. |
| Protriptyline | The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Entrectinib. |
| Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Entrectinib. |
| Quetiapine | The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Entrectinib. |
| Quinidine | The risk or severity of QTc prolongation can be increased when Quinidine is combined with Entrectinib. |
| Quinine | The metabolism of Entrectinib can be increased when combined with Quinine. |
| Quinupristin | The metabolism of Entrectinib can be decreased when combined with Quinupristin. |
| Raloxifene | The metabolism of Entrectinib can be decreased when combined with Raloxifene. |
| Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Entrectinib. |
| Regorafenib | The serum concentration of Regorafenib can be increased when it is combined with Entrectinib. |
| Relugolix | The serum concentration of Relugolix can be increased when it is combined with Entrectinib. |
| Remdesivir | The metabolism of Entrectinib can be decreased when combined with Remdesivir. |
| Revefenacin | The serum concentration of Revefenacin can be increased when it is combined with Entrectinib. |
| Ribociclib | The metabolism of Entrectinib can be decreased when combined with Ribociclib. |
| Rifabutin | The metabolism of Entrectinib can be increased when combined with Rifabutin. |
| Rifampicin | The metabolism of Entrectinib can be increased when combined with Rifampicin. |
| Rifamycin | The metabolism of Entrectinib can be increased when combined with Rifamycin. |
| Rifapentine | The metabolism of Entrectinib can be increased when combined with Rifapentine. |
| Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Entrectinib. |
| Rilonacept | The metabolism of Entrectinib can be increased when combined with Rilonacept. |
| Rilpivirine | The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Entrectinib. |
| Rimegepant | The serum concentration of Rimegepant can be increased when it is combined with Entrectinib. |
| Riociguat | The serum concentration of Riociguat can be increased when it is combined with Entrectinib. |
| Ripretinib | The serum concentration of Ripretinib can be increased when it is combined with Entrectinib. |
| Risperidone | The risk or severity of QTc prolongation can be increased when Risperidone is combined with Entrectinib. |
| Ritonavir | The metabolism of Entrectinib can be decreased when combined with Ritonavir. |
| Rivaroxaban | The serum concentration of Rivaroxaban can be increased when it is combined with Entrectinib. |
| Rofecoxib | The metabolism of Entrectinib can be increased when combined with Rofecoxib. |
| Roflumilast | The metabolism of Entrectinib can be decreased when combined with Roflumilast. |
| Romidepsin | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Entrectinib. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Ropivacaine. |
| Rosoxacin | The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Entrectinib. |
| Rosuvastatin | The metabolism of Entrectinib can be decreased when combined with Rosuvastatin. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Entrectinib. |
| Rucaparib | The metabolism of Entrectinib can be decreased when combined with Rucaparib. |
| Rufinamide | The metabolism of Entrectinib can be increased when combined with Rufinamide. |
| Rupatadine | The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Entrectinib. |
| Salbutamol | The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Entrectinib. |
| Salmeterol | The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Entrectinib. |
| Salmon calcitonin | The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Entrectinib. |
| Saquinavir | The metabolism of Entrectinib can be decreased when combined with Saquinavir. |
| Sarilumab | The metabolism of Entrectinib can be increased when combined with Sarilumab. |
| Satralizumab | The serum concentration of Entrectinib can be decreased when it is combined with Satralizumab. |
| Secobarbital | The metabolism of Entrectinib can be increased when combined with Secobarbital. |
| Secukinumab | The metabolism of Entrectinib can be increased when combined with Secukinumab. |
| Selexipag | The serum concentration of Selexipag can be increased when it is combined with Entrectinib. |
| Selpercatinib | The risk or severity of QTc prolongation can be increased when Selpercatinib is combined with Entrectinib. |
| Selumetinib | The serum concentration of Selumetinib can be increased when it is combined with Entrectinib. |
| Sertindole | The risk or severity of QTc prolongation can be increased when Sertindole is combined with Entrectinib. |
| Sevoflurane | The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Entrectinib. |
| Sildenafil | The serum concentration of Sildenafil can be increased when it is combined with Entrectinib. |
| Silodosin | The excretion of Silodosin can be decreased when combined with Entrectinib. |
| Siltuximab | The metabolism of Entrectinib can be increased when combined with Siltuximab. |
| Simeprevir | The metabolism of Entrectinib can be decreased when combined with Simeprevir. |
| Simvastatin | The serum concentration of Simvastatin can be increased when it is combined with Entrectinib. |
| Siponimod | The metabolism of Entrectinib can be decreased when combined with Siponimod. |
| Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Entrectinib. |
| Sitagliptin | The serum concentration of Sitagliptin can be increased when it is combined with Entrectinib. |
| Sitaxentan | The metabolism of Entrectinib can be decreased when combined with Sitaxentan. |
| Sofosbuvir | The serum concentration of Sofosbuvir can be increased when it is combined with Entrectinib. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Entrectinib. |
| Somatostatin | The metabolism of Entrectinib can be decreased when combined with Somatostatin. |
| Somatrogon | The metabolism of Entrectinib can be increased when combined with Somatrogon. |
| Sorafenib | The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Entrectinib. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Sotalol is combined with Entrectinib. |
| Sotorasib | The serum concentration of Entrectinib can be decreased when it is combined with Sotorasib. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Entrectinib. |
| St. John’s Wort | The metabolism of Entrectinib can be increased when combined with St. John’s Wort. |
| Stiripentol | The metabolism of Entrectinib can be increased when combined with Stiripentol. |
| Sulfamethoxazole | The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Entrectinib. |
| Sulfinpyrazone | The metabolism of Entrectinib can be increased when combined with Sulfinpyrazone. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Entrectinib. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Entrectinib. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Sultopride is combined with Entrectinib. |
| Sunitinib | The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Entrectinib. |
| Suvorexant | The metabolism of Entrectinib can be decreased when combined with Suvorexant. |
| Tacrolimus | The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Entrectinib. |
| Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Entrectinib. |
| Tamoxifen | The metabolism of Entrectinib can be increased when combined with Tamoxifen. |
| Tasimelteon | The metabolism of Entrectinib can be decreased when combined with Tasimelteon. |
| Tazemetostat | The metabolism of Entrectinib can be decreased when combined with Tazemetostat. |
| Technetium | The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Entrectinib. |
| Tecovirimat | The metabolism of Entrectinib can be increased when combined with Tecovirimat. |
| Tegaserod | The serum concentration of Tegaserod can be increased when it is combined with Entrectinib. |
| Telaprevir | The metabolism of Entrectinib can be decreased when combined with Telaprevir. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Telavancin is combined with Entrectinib. |
| Telithromycin | The metabolism of Entrectinib can be decreased when combined with Telithromycin. |
| Telotristat ethyl | The serum concentration of Entrectinib can be decreased when it is combined with Telotristat ethyl. |
| Temsirolimus | The serum concentration of Temsirolimus can be increased when it is combined with Entrectinib. |
| Teniposide | The metabolism of Entrectinib can be decreased when combined with Teniposide. |
| Tenofovir | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Entrectinib. |
| Tenofovir disoproxil | The serum concentration of Tenofovir disoproxil can be increased when it is combined with Entrectinib. |
| Tepotinib | The serum concentration of Tepotinib can be increased when it is combined with Entrectinib. |
| Terbinafine | The metabolism of Entrectinib can be increased when combined with Terbinafine. |
| Terbutaline | The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Entrectinib. |
| Terfenadine | The metabolism of Entrectinib can be decreased when combined with Terfenadine. |
| Teriparatide | The therapeutic efficacy of Teriparatide can be decreased when used in combination with Entrectinib. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Entrectinib. |
| Testosterone | The metabolism of Entrectinib can be increased when combined with Testosterone. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Entrectinib. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Tetracaine. |
| Tetracycline | The metabolism of Entrectinib can be decreased when combined with Tetracycline. |
| Tezacaftor | The serum concentration of Tezacaftor can be increased when it is combined with Entrectinib. |
| Thiamylal | The metabolism of Entrectinib can be increased when combined with Thiamylal. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Entrectinib. |
| Thiothixene | The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Entrectinib. |
| Thyroid, porcine | The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Entrectinib. |
| Thyrotropin alfa | The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Entrectinib. |
| Ticagrelor | The metabolism of Entrectinib can be decreased when combined with Ticagrelor. |
| Timolol | The risk or severity of QTc prolongation can be increased when Timolol is combined with Entrectinib. |
| Tioconazole | The metabolism of Entrectinib can be decreased when combined with Tioconazole. |
| Tipranavir | The metabolism of Entrectinib can be decreased when combined with Tipranavir. |
| Tivozanib | The serum concentration of Tivozanib can be increased when it is combined with Entrectinib. |
| Tizanidine | The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Entrectinib. |
| Tocilizumab | The metabolism of Entrectinib can be increased when combined with Tocilizumab. |
| Tolterodine | The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Entrectinib. |
| Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Entrectinib. |
| Topiramate | The metabolism of Entrectinib can be increased when combined with Topiramate. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Entrectinib. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Toremifene is combined with Entrectinib. |
| Trastuzumab | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Entrectinib. |
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Entrectinib. |
| Treprostinil | The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Entrectinib. |
| Triamcinolone | The metabolism of Entrectinib can be increased when combined with Triamcinolone. |
| Triclabendazole | The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Entrectinib. |
| Trilaciclib | The serum concentration of Trilaciclib can be increased when it is combined with Entrectinib. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Entrectinib. |
| Trimethadione | The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Entrectinib. |
| Trimipramine | The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Entrectinib. |
| Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Entrectinib. |
| Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Entrectinib. |
| Troglitazone | The metabolism of Entrectinib can be increased when combined with Troglitazone. |
| Troleandomycin | The metabolism of Entrectinib can be decreased when combined with Troleandomycin. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Entrectinib. |
| Tucatinib | The metabolism of Tucatinib can be decreased when combined with Entrectinib. |
| Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Entrectinib. |
| Umeclidinium | The serum concentration of Umeclidinium can be increased when it is combined with Entrectinib. |
| Valproic acid | The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Entrectinib. |
| Vandetanib | The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Entrectinib. |
| Vardenafil | The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Entrectinib. |
| Velpatasvir | The serum concentration of Velpatasvir can be increased when it is combined with Entrectinib. |
| Vemurafenib | The metabolism of Entrectinib can be increased when combined with Vemurafenib. |
| Venetoclax | The metabolism of Entrectinib can be decreased when combined with Venetoclax. |
| Verapamil | The metabolism of Entrectinib can be decreased when combined with Verapamil. |
| Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Entrectinib. |
| Vilanterol | The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Entrectinib. |
| Viloxazine | The metabolism of Entrectinib can be decreased when combined with Viloxazine. |
| Vinblastine | The metabolism of Entrectinib can be increased when combined with Vinblastine. |
| Vincristine | The excretion of Vincristine can be decreased when combined with Entrectinib. |
| Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Entrectinib. |
| Vitamin E | The metabolism of Entrectinib can be increased when combined with Vitamin E. |
| Voclosporin | The serum concentration of Voclosporin can be increased when it is combined with Entrectinib. |
| Vorapaxar | The metabolism of Entrectinib can be decreased when combined with Vorapaxar. |
| Voriconazole | The metabolism of Entrectinib can be decreased when combined with Voriconazole. |
| Vorinostat | The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Entrectinib. |
| Voxelotor | The serum concentration of Entrectinib can be increased when it is combined with Voxelotor. |
| Voxilaprevir | The serum concentration of Voxilaprevir can be increased when it is combined with Entrectinib. |
| Warfarin | The metabolism of Entrectinib can be increased when combined with Warfarin. |
| Zafirlukast | The metabolism of Entrectinib can be decreased when combined with Zafirlukast |
Pregnancy and Lactation
US FDA pregnancy category: Not assigned.
Pregnancy
This drug can harm a developing fetus. Verify negative pregnancy status in females of reproductive potential prior to initiating therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Advise female patients of reproductive potential to use effective contraception during therapy and for at least 5 weeks after. Advise male patients with female partners of reproductive potential to use effective contraception during therapy and for 3 months after.
Lactation
Use is not recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
The effects in the nursing infant are unknown. Because of the potential for adverse reactions in breastfed infants from this drug, advise lactating women to discontinue breastfeeding during therapy and for 7 days after.
How should this medicine be used?
Entrectinib comes as a capsule to take by mouth. It is usually taken with or without food once daily. Take entrectinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take entrectinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the capsules whole; do not open, chew, or crush them.
If you vomit immediately after you take entrectinib, take another dose as soon as possible.
Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before taking entrectinib,
- tell your doctor and pharmacist if you are allergic to entrectinib, any other medications, or any of the ingredients in entrectinib capsules. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the following: aprepitant (Emend), certain antifungal medications such as fluconazole (Diflucan), itraconazole (Omel, Sporanox), or ketoconazole; certain medications for arrhythmias such as amiodarone (Nexterone, Pacerone), procainamide, quinidine (in Nuedexta), and sotalol (Betapace, Sorine, Sotylize); azithromycin (Zithromax); clarithromycin (Biaxin, in Prevpac); diltiazem (Cardizem, Tiazac, others); erythromycin (E.E.S., Erythrocin, others); enzalutamide (Xtandi); certain HIV medications such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra, others), or saquinavir (Invirase); lithium (Lithobid); modafinil (Provigil); nefazodone; oxcarbazepine (Trileptal); phenobarbital; phenytoin (Dilantin, Phenytek); pioglitazone (Actos, in Actoplus, Duetact, Oseni); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, in Rifater); oral steroids such as dexamethasone, methylprednisolone (Medrol), and prednisone (Rayos); and verapamil (Calan). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with entrectinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor what herbal products you are taking, especially St. John’s Wort.
- tell your doctor if you have or have ever had a nervous system condition, a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), a slow or irregular heartbeat, a heart attack, heart failure, or heart or liver disease.
- tell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for at least 5 weeks after your final dose. If you are a male, you and your partner should use birth control during your treatment with entrectinib and for 3 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while taking entrectinib, call your doctor immediately. Entrectinib may harm the fetus.
- tell your doctor if you are breastfeeding. You should not breastfeed while you are taking entrectinib and for 7 days after the final dose.
- you should know that entrectinib may make cause dizziness or confusion. Do not drive a car or operate machinery until you know how this medication affects you.
References
